Patient outcomes (N = 33)
| Confirmed response rate | 48% (95% CI, 30-66) |
| Complete response | 1 (3%) |
| Very good partial response | 5 (15%) |
| Partial response | 10 (30%) |
| Stable disease | 11 (33%) |
| Not available* | 2 (6%) |
| Organ response | 5 (15%) |
| Heart involvement | 27 |
| Response | 4 (15%) |
| Kidney involvement | 12 |
| Response | 2 (17%) |
| Liver involvement | 1 |
| Response | 0 |
| Median time to hematologic response (PR+) | 1.9 mo (range: 0.9-11.3) |
| Median duration of response† | 19 mo (95% CI: 8.3-NA) |
| Median overall survival† | 27.9 mo (95% CI: 14.6-NA) |
| 12 mo | 76% (95% CI: 62-92) |
| Median progression-free survival† | 14.1 (95% CI: 9.7-21.1) |
| 12 mo | 59% (95% CI: 44-79) |
| Confirmed response rate | 48% (95% CI, 30-66) |
| Complete response | 1 (3%) |
| Very good partial response | 5 (15%) |
| Partial response | 10 (30%) |
| Stable disease | 11 (33%) |
| Not available* | 2 (6%) |
| Organ response | 5 (15%) |
| Heart involvement | 27 |
| Response | 4 (15%) |
| Kidney involvement | 12 |
| Response | 2 (17%) |
| Liver involvement | 1 |
| Response | 0 |
| Median time to hematologic response (PR+) | 1.9 mo (range: 0.9-11.3) |
| Median duration of response† | 19 mo (95% CI: 8.3-NA) |
| Median overall survival† | 27.9 mo (95% CI: 14.6-NA) |
| 12 mo | 76% (95% CI: 62-92) |
| Median progression-free survival† | 14.1 (95% CI: 9.7-21.1) |
| 12 mo | 59% (95% CI: 44-79) |